Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immix Biopharma, Inc. - Common Stock (NQ:IMMX)

4.990 +0.100 (+2.04%)
Streaming Delayed Price Updated: 11:17 AM EST, Jan 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 492,373
Open 4.900
Bid (Size) 4.970 (500)
Ask (Size) 5.000 (600)
Prev. Close 4.890
Today's Range 4.890 - 5.150
52wk Range 1.340 - 7.730
Shares Outstanding 33,577,873
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Immix Biopharma (IMMX) Shares Slip As Investors Focus On Plans To Offer And Sell $750 Million In Securities ↗
Immix Biopharma Inc (NASDAQ: IMMX) shares are trading lower Monday after the company filed a new shelf registration statement. 
Via Benzinga
News headline image
Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
From Immix Biopharma, Inc.
Via GlobeNewswire

Performance

YTD
-8.1%
-8.1%
1 Month
-14.1%
-14.1%
3 Month
+61.5%
+61.5%
6 Month
+72.1%
+72.1%
1 Year
+153.3%
+153.3%

More News

Read More
News headline image
Nasdaq, S&P 500 Futures Rise Ahead Of Fed Decision This Week: Why NFLX, CFLT, BA, LLY, IMMX Are On Traders' Radar ↗
Via Stocktwits
Topics ETFs Economy Government
News headline image
Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Via Benzinga
News headline image
Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Via Benzinga
News headline image
Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Via Benzinga
News headline image
Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma to Present at the Stifel 2025 Healthcare Conference
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Announces Other Serious Diseases Strategy
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Attends FDA CEO Forum in Washington DC
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
The trading volume of these stocks is deviating from the norm in today's session. ↗
Via Chartmill
News headline image
On Tuesday, there are stocks with unusual volume. Let's take a look. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Via Benzinga

Frequently Asked Questions

Is Immix Biopharma, Inc. - Common Stock publicly traded?
Yes, Immix Biopharma, Inc. - Common Stock is publicly traded.
What exchange does Immix Biopharma, Inc. - Common Stock trade on?
Immix Biopharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Immix Biopharma, Inc. - Common Stock?
The ticker symbol for Immix Biopharma, Inc. - Common Stock is IMMX on the Nasdaq Stock Market
What is the current price of Immix Biopharma, Inc. - Common Stock?
The current price of Immix Biopharma, Inc. - Common Stock is 4.990
When was Immix Biopharma, Inc. - Common Stock last traded?
The last trade of Immix Biopharma, Inc. - Common Stock was at 01/22/26 11:17 AM ET
What is the market capitalization of Immix Biopharma, Inc. - Common Stock?
The market capitalization of Immix Biopharma, Inc. - Common Stock is 167.55M
How many shares of Immix Biopharma, Inc. - Common Stock are outstanding?
Immix Biopharma, Inc. - Common Stock has 168M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.